NasdaqCM:BIOC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. More Details


Snowflake Analysis

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Biocept's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BIOC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: BIOC's weekly volatility has decreased from 32% to 15% over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

21.3%

BIOC

1.8%

US Biotechs

2.3%

US Market


1 Year Return

103.1%

BIOC

45.9%

US Biotechs

23.7%

US Market

Return vs Industry: BIOC exceeded the US Biotechs industry which returned 45.9% over the past year.

Return vs Market: BIOC exceeded the US Market which returned 23.7% over the past year.


Shareholder returns

BIOCIndustryMarket
7 Day21.3%1.8%2.3%
30 Day34.9%5.7%4.7%
90 Day43.8%25.0%14.5%
1 Year103.1%103.1%48.3%45.9%26.5%23.7%
3 Year-93.9%-93.9%23.3%16.5%45.0%35.4%
5 Year-99.5%-99.5%58.8%46.6%126.2%100.9%

Long-Term Price Volatility Vs. Market

How volatile is Biocept's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Biocept undervalued compared to its fair value and its price relative to the market?

4.08x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BIOC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BIOC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BIOC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: BIOC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BIOC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BIOC is good value based on its PB Ratio (4.1x) compared to the US Biotechs industry average (4.4x).


Next Steps

Future Growth

How is Biocept forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

66.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIOC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: BIOC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BIOC's is expected to become profitable in the next 3 years.

Revenue vs Market: BIOC's revenue (41.1% per year) is forecast to grow faster than the US market (10.6% per year).

High Growth Revenue: BIOC's revenue (41.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BIOC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Biocept performed over the past 5 years?

-10.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BIOC is currently unprofitable.

Growing Profit Margin: BIOC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BIOC is unprofitable, and losses have increased over the past 5 years at a rate of 10.3% per year.

Accelerating Growth: Unable to compare BIOC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIOC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: BIOC has a negative Return on Equity (-119.06%), as it is currently unprofitable.


Next Steps

Financial Health

How is Biocept's financial position?


Financial Position Analysis

Short Term Liabilities: BIOC's short term assets ($28.8M) exceed its short term liabilities ($10.1M).

Long Term Liabilities: BIOC's short term assets ($28.8M) exceed its long term liabilities ($1.3M).


Debt to Equity History and Analysis

Debt Level: BIOC's debt to equity ratio (1%) is considered satisfactory.

Reducing Debt: BIOC's debt to equity ratio has reduced from 72.1% to 1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BIOC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BIOC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 11% each year


Next Steps

Dividend

What is Biocept current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BIOC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BIOC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIOC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIOC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BIOC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Mike Nall (57 yo)

7.42yrs

Tenure

US$1,216,055

Compensation

Mr. Michael W. Nall, also known as Mike, has been the Chief Executive Officer and President at Biocept, Inc. since August 26, 2013. Mr. Nall has over 30 years of leadership experience in healthcare sales, ...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD1.22M) is above average for companies of similar size in the US market ($USD529.89K).

Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Nall
CEO, President & Director7.42yrsUS$1.22m0.0031%
$ 2.7k
Timothy Kennedy
CFO, Senior VP of Operations & Corporate Secretary4.5yrsUS$826.51k0.0022%
$ 1.9k
Soon Kap Hahn
24yrsno datano data
Pavel Tsinberg
Director of Technology Development3.33yrsno datano data
Michael Brown
General Counsel and Compliance & Privacy Officer3.25yrsno datano data
David Moskowitz
Vice President of Strategy & Corporate Communications4.25yrsno datano data
Michael Terry
Senior Vice President of Corporate Developmentno datano datano data
Brenda Tang
Senior Director of Marketing1yrno datano data
Gary Marchetti
Senior Director of People & Culture/Facilities1yrno datano data
Veena Singh
Senior Medical Director6.08yrsUS$115.22kno data
Michael Dugan
Senior VP0.42yrno data0.0043%
$ 3.7k

3.8yrs

Average Tenure

57yo

Average Age

Experienced Management: BIOC's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Nall
CEO, President & Director7.42yrsUS$1.22m0.0031%
$ 2.7k
M. Wilson
Interim Chair & Lead Independent Director1yrUS$82.25k0.00057%
$ 496.3
Ivor Royston
Independent Director11yrsUS$67.25k0.00043%
$ 374.4
David Hale
Director9.83yrsUS$128.50k0.0033%
$ 2.9k
Lyle Arnold
Member of Scientific Advisory Boardno dataUS$287.43k0.0022%
$ 2.0k
Samuel Riccitelli
Independent Director0.25yrno datano data
Claire Reiss
Chairwoman Emeritus9.75yrsno datano data
Marsha Chandler
Independent Director7.17yrsUS$66.00k0.00017%
$ 148.0
Fred Hirsch
Member of Clinical Advisory Boardno datano datano data
Bruce Gerhardt
Independent Director10.25yrsUS$64.75k0.0024%
$ 2.1k

8.9yrs

Average Tenure

72yo

Average Age

Experienced Board: BIOC's board of directors are considered experienced (8.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 217.3%.


Top Shareholders

Company Information

Biocept, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biocept, Inc.
  • Ticker: BIOC
  • Exchange: NasdaqCM
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$87.079m
  • Shares outstanding: 13.40m
  • Website: https://biocept.com

Number of Employees


Location

  • Biocept, Inc.
  • 9955 Mesa Rim Road
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIOCNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2014
B002BST (Boerse-Stuttgart)YesCommon StockDEEURFeb 2014
B003DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014

Biography

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/23 00:11
End of Day Share Price2021/01/22 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.